GlassScriptPhysician profile
Sathish L Magge
NPI 1891791729
$4,867.73
in general payments reported to CMS, 2019-2025
36 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $341 · 2021: $550 · 2022: $910 · 2023: $998 · 2024: $714 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Travel and Lodging: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.90 |
| Travel and Lodging | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $522.66 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $504.37 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $494.93 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.25 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $360.33 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $340.74 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $340.38 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $209.30 | 2021-2024 | In.Pact Admiral, Mycarelink |
| Bayer Healthcare Pharmaceuticals INC. | $193.99 | 2021-2025 | |
| Amgen INC. | $161.44 | 2019-2025 | Repatha |
| Pfizer INC. | $150.59 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $117.90 | 2021-2022 | |
| Abbvie INC. | $117.75 | 2019-2024 | |
| Amarin Pharma, INC. | $113.35 | 2019-2022 | |
| Novo Nordisk INC | $95.63 | 2019-2024 | Wegovy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $71.80 | 2019-2025 | Watchman Access System |
| Medtronic Vascular, INC. | $64.84 | 2019 | |
| Edwards Lifesciences Corporation | $60.30 | 2024 | |
| Lundbeck LLC | $54.27 | 2019 | |
| Portola Pharmaceuticals, LLC | $51.61 | 2019 | |
| Acadia Pharmaceuticals INC | $50.85 | 2025 | Daybue |
| Chiesi USA, INC. | $45.29 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $44.41 | 2023-2024 | Inpefa |
| Azurity Pharmaceuticals, INC. | $39.88 | 2025 | Edarbi |
| Abiomed | $39.45 | 2025 | |
| Impulse Dynamics (USA) INC. | $38.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.02 | 2020-2021 | |
| Abbott Laboratories | $24.09 | 2024 | Amplatzer Amulet |
| Alnylam Pharmaceuticals INC. | $23.36 | 2022 | |
| Lilly USA, LLC | $19.31 | 2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $19.29 | 2021 | |
| Glaxosmithkline, LLC. | $15.72 | 2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2019 | |
| Esperion Therapeutics, INC. | $14.50 | 2021 | |
| Daiichi Sankyo INC. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathish Magge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.